GE HealthCare Technologies Inc. (GEHC) - Stock Analysis

Last updated: Jul 26, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Constructive healthcare setup after Q2 2026 beat EPS and revenue expectations, with record orders, record backlog, and growth across every segment. Commercial catalysts include a $500M Catholic Health partnership and FDA clearance for MIM Contour ProtegeAI+ 2.0.

Loading chart data...

Idea window: 7/30/2026 – 8/6/2026Sector: Healthcare

AI Analyst Overview

Last Price
$69.94
Market Cap
$28.07B
1D Return
-2.73%
YTD Return
-14.61%

Loading chart data...

Valuation Metrics

P/E
18.7
P/B
2.6
P/S
1.4
EV/EBITDA
12.1
Div Yield
0.23%

Price Behavior

4.5

Key Price Behavior Insights: • Weak momentum • Lower-highs trend • Support holding Support Level: $60.6 Resistance Level: $62.0–$63.2 GEHC finished near the low of its last month range, with lower highs/lows and a break below $62.0–$63.2 signaling weak short-term momentum, while $60.6 remains the key support to hold for any rebound.

GEHC
SupportTest

Sentiment & News

Key News Insights: • Care alliance • Product launches • Legal overhang GE HealthCare paired major expansion and product launches with solid guidance and dividend support, but ongoing securities investigations, CFO turnover, and margin pressure temper the outlook.

growth
legalrisk
AI

AI Summary

5.8
Neutral

GEHC still has credible commercial momentum from large partnerships and AI/software wins, but the stock's real investment test is now whether management can stabilize margins, absorb input-cost inflation, and resolve governance/legal overhangs without another earnings disappointment.

MarginPressure
Legal
Execution
AI summary updated 4 days ago

Description

GE HealthCare Technologies develops, manufactures and sells medical devices, diagnostic agents and supporting digital solutions for use in patient diagnosis, treatment and monitoring across North America, Europe, Asia and other markets. Organized into four segments—Imaging, Ultrasound, Patient Care Solutions and Pharmaceutical Diagnostics—the company supplies imaging systems (including CT, MR and molecular imaging), point-of-care and surgical ultrasound, bedside monitoring and therapeutic devices, and contrast media and radiopharmaceuticals. Incorporated in 2022, it is headquartered in Chicago, Illinois.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Jul 30Aug 6GEHCGE HealthCare Technologies Inc.
Constructive healthcare setup after Q2 2026 beat EPS and revenue expectations, with record orders, record backlog, and growth across every segment. Commercial catalysts include a $500M Catholic Health partnership and FDA clearance for MIM Contour ProtegeAI+ 2.0.
Active+0.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.